secwatch.observer — SEC 8-K summary
======================================

Issuer:     MiNK Therapeutics, Inc. (INKT)
CIK:        0001840229
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001171843-25-005405
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiNK Therapeutics Q2 2025 net loss $4.2M; extends runway with $13M raise; GvHD grants awarded
--------------------------------------------------------------------------------

- Cash at Q2 end $1.6M; raised $13M post-quarter; runway extended beyond mid-2026.
- Net loss Q2 2025 $4.2M ($1.06/shr) vs $2.7M ($0.73/shr) in Q2 2024.
- Durable complete remission in metastatic testicular cancer published; patient disease-free >2 years.
- DOD STTR grant and new clinical grant awarded for iNKT cell therapy in GvHD; trial target 2H2025.
- Phase 2 gastric cancer trial of agenT-797 expects additional readouts in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840229/000117184325005405/0001171843-25-005405-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840229/000117184325005405/f8k_081425.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-005405

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer